Lotrisone Cream

Pronunciation: kloe-TRIM-a-zole/BAY-ta-METH-a-sone
Generic Name: Clotrimazole/Betamethasone
Brand Name: Lotrisone

Lotrisone Cream is used for:

Treating certain fungal skin infections, including ringworm, athlete's foot, and jock itch. It also relieves redness, swelling, and itching associated with infection.

Lotrisone Cream is an antifungal and corticosteroid combination. It works by weakening the cell membrane of certain fungi. It also acts as an anti-inflammatory and anti-itching agent.

Do NOT use Lotrisone Cream if:

• you are allergic to any ingredient in Lotrisone Cream


• you are taking pimozide or an ergot alkaloid (eg, ergotamine)

Contact your doctor or health care provider right away if any of these apply to you.

Before using Lotrisone Cream:

Some medical conditions may interact with Lotrisone Cream. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

• if you are pregnant, planning to become pregnant, or are breast-feeding


• if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement


• if you have allergies to medicines or other substances


• if you have diaper rash, eczema, measles, tuberculosis (TB) or a positive TB skin test, chickenpox, shingles, or thinning of the skin


• if you have recently received a vaccination

Some MEDICINES MAY INTERACT with Lotrisone Cream. Tell your health care provider if you are taking any other medicines, especially any of the following:

• Clarithromycin because the risk of certain side effects may be increased


• Barbiturates (eg, phenobarbital), carbamazepine, hydantoins (eg, phenytoin), or rifampin because they may decrease Lotrisone Cream's effectiveness


• Ergot alkaloids (eg, ergotamine), imatinib, live vaccines, macrolide immunosuppressants (eg, tacrolimus), pimozide, or ritodrine because their actions and the risk of their side effects may be increased by Lotrisone Cream


• Hydantoins (eg, phenytoin) or interleukin-2 because their effectiveness may be decreased by Lotrisone Cream

This may not be a complete list of all interactions that may occur. Ask your health care provider if Lotrisone Cream may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Lotrisone Cream:

Use Lotrisone Cream as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Wash your hands before and after applying Lotrisone Cream.


• Wash and completely dry the affected area.


• Gently rub the medicine into the affected and surrounding areas until it is evenly distributed.


• Do not bandage or wrap the affected area unless directed otherwise by your doctor.


• If you are using Lotrisone Cream in the groin area, use only for 2 weeks and apply the cream sparingly. Wear loose-fitting clothing. Notify your doctor if your condition persists after 2 weeks.


• Use Lotrisone Cream on a regular schedule to get the most benefit from it.


• To clear up your infection completely, use Lotrisone Cream for the full course of treatment. Keep using it even if you feel better in a few days.


• Notify your doctor if there is no improvement of your symptoms after 1 week of treatment on the groin or body or after 2 weeks of treatment on the feet.


• If you miss a dose of Lotrisone Cream, use it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule.

Ask your health care provider any questions you may have about how to use Lotrisone Cream.

Important safety information:

• Lotrisone Cream has a corticosteroid in it. Before you start any new medicine, check the label to see if it has a corticosteroid in it too. If it does or if you are not sure, check with your doctor or pharmacist.


• Lotrisone Cream is for external use only. Avoid getting Lotrisone Cream in the eyes, vagina, mouth, or nose. If Lotrisone Cream gets in the eyes, immediately wash out with cool tap water.


• Be sure to use Lotrisone Cream for the full course of treatment. If you do not, the medicine may not clear up your infection completely. The fungus could also become less sensitive to this or other medicines. This could make the infection harder to treat in the future.


• Do NOT use more than the recommended dose or use for longer than prescribed without checking with your doctor.


• Do not apply Lotrisone Cream over large areas of the body without first checking with your doctor.


• Do not use Lotrisone Cream for other skin conditions at a later time.


• Talk with your doctor before you use any other medicines or cleansers on your skin.


• Do not use Lotrisone Cream for diaper rash.


• Serious side effects may occur if too much of Lotrisone Cream is absorbed through the skin. This may be more likely to occur if you use Lotrisone Cream over a large area of the body. It may also be more likely if you wrap or bandage the area after you apply Lotrisone Cream. The risk is greater in children. Do not use more than the prescribed dose. Contact your doctor right away if you develop unusual weight gain (especially in the face), muscle weakness, increased thirst or urination, confusion, unusual drowsiness, severe or persistent headache, or vision changes. Discuss any questions or concerns with your doctor.


• Use Lotrisone Cream with caution in the ELDERLY; they may be more sensitive to its effects, especially thinning skin.


• Corticosteroids may affect growth rate in CHILDREN and teenagers in some cases. They may need regular growth checks while using a corticosteroid.


• Lotrisone Cream should not be used in CHILDREN younger than 17 years old; safety and effectiveness in these children have not been confirmed.


• PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Lotrisone Cream while you are pregnant. It is not known if Lotrisone Cream is found in breast milk. If you are or will be breast-feeding while you use Lotrisone Cream, check with your doctor. Discuss any possible risks to your baby.

Possible side effects of Lotrisone Cream:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Dry skin; mild burning or stinging at the application site.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); acne-like rash; excessive hair growth; inflamed hair follicles; inflammation around the mouth; irritation, itching, peeling, redness, blistering, swelling, oozing, or severe burning at the application site; spider veins; thinning, softening, or discoloration of the skin; unusual bruising.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: Lotrisone side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Lotrisone Cream may be harmful if swallowed.

Proper storage of Lotrisone Cream:

Store Lotrisone Cream at 77 degrees F (25 degrees C). Brief storage at temperatures between 59 and 86 degrees F (15 and 30 degrees C) is permitted. Store away from heat, moisture, and light. Do not store in the bathroom. Keep Lotrisone Cream out of the reach of children and pets.

General information:

• If you have any questions about Lotrisone Cream, please talk with your doctor, pharmacist, or other health care provider.


• Lotrisone Cream is to be used only by the patient for whom it is prescribed. Do not share it with other people.


• If your symptoms do not improve or if they become worse, check with your doctor.


• Check with your pharmacist about how to dispose of unused medicine.

This information is summary only. It does not contain all information about Lotrisone Cream. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Lotrisone resources

• Lotrisone Side Effects (in more detail)
• Lotrisone Use in Pregnancy & Breastfeeding
• Lotrisone Drug Interactions
• Lotrisone Support Group
• 0 Reviews for Lotrisone - Add your own review/rating

Compare Lotrisone with other medications

• Tinea Corporis
• Tinea Cruris
• Tinea Pedis

Engerix-B

Pronunciation: hep-ah-TY-tiss
Generic Name: Hepatitis B Vaccine (Recombinant)
Brand Name: Examples include Engerix-B and Recombivax HB

Engerix-B is used for:

Preventing hepatitis B infection.

Engerix-B is a vaccine. It works by stimulating the body to produce antibodies against hepatitis B infection.

Do NOT use Engerix-B if:

• you are allergic to any ingredient in Engerix-B, including yeast


• you have had an allergic reaction to a hepatitis B vaccine in the past

Contact your doctor or health care provider right away if any of these apply to you.

Before using Engerix-B:

Tell your health care provider if you have any medical conditions, especially if any of the following apply to you:

• if you are pregnant, planning to become pregnant, or are breast-feeding


• if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement


• if you have allergies to medicines, foods, or other substances


• if you are allergic to latex


• if you have a weakened immune system, heart or lung disease, a fever, an infection, an illness, a tumor, or multiple sclerosis


• if you are on dialysis, you have or might have been recently exposed to hepatitis B, or if you have traveled to areas that are high-risk for hepatitis B


• if the patient is a premature infant

Some MEDICINES MAY INTERACT with Engerix-B. Tell your health care provider if you are taking any other medicines, especially any of the following:

• Immunosuppressive therapy (eg, cyclosporine) because it may decrease Engerix-B's effectiveness

This may not be a complete list of all interactions that may occur. Ask your health care provider if Engerix-B may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Engerix-B:

Use Engerix-B as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Engerix-B is usually given as an injection at your doctor's office, hospital, or clinic. Contact your health care provider if you have any questions.


• If you miss a dose of Engerix-B, contact your doctor right away.

Ask your health care provider any questions you may have about how to use Engerix-B.

Important safety information:

• Engerix-B has noninfectious hepatitis B antigens in it. It cannot cause you to develop the hepatitis B infection.


• Before receiving this vaccine, tell your doctor about any illnesses you may have or if you are sick.


• For Engerix-B to be effective, you must complete all doses. It is best to begin the vaccinations 6 months before travel, if possible, if that is the reason for receiving the vaccination.


• Contact your doctor at once if you are exposed to the virus through blood, a human bite, or sexual contact.


• The length of protection against the virus from Engerix-B is not known, nor is it a guarantee that the vaccine will protect you from the hepatitis B virus.


• PREGNANCY and BREAST-FEEDING: If you become pregnant, discuss with your doctor the benefits and risks of using Engerix-B during pregnancy. It is unknown if Engerix-B is excreted in breast milk. If you are or will be breast-feeding while you are using Engerix-B, check with your doctor or pharmacist to discuss the risks to your baby.

Possible side effects of Engerix-B:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Diarrhea; dizziness; fatigue; general feeling of discomfort; headache; irritability; loss of appetite; mild fever or sore throat; nausea; pain, swelling, or redness at the injection site; runny nose; tiredness; weakness.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue; unusual hoarseness); fainting; fast or irregular heartbeat; red, swollen, blistered, or peeling skin; severe or persistent dizziness; unusual bruising or bleeding.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: Engerix-B side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.

Proper storage of Engerix-B:

Engerix-B is usually handled and stored by a health care provider. If you are using Engerix-B at home, store Engerix-B as directed by your pharmacist or health care provider. Keep Engerix-B out of the reach of children and away from pets.

General information:

• If you have any questions about Engerix-B, please talk with your doctor, pharmacist, or other health care provider.


• Engerix-B is to be used only by the patient for whom it is prescribed. Do not share it with other people.


• If your symptoms do not improve or if they become worse, check with your doctor.


• Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Engerix-B. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Engerix-B resources

• Engerix-B Side Effects (in more detail)
• Engerix-B Use in Pregnancy & Breastfeeding
• Engerix-B Drug Interactions
• Engerix-B Support Group
• 0 Reviews for Engerix-B - Add your own review/rating

• Engerix-B Advanced Consumer (Micromedex) - Includes Dosage Information


• Engerix-B Consumer Overview

Compare Engerix-B with other medications

• Hepatitis B Prevention

Abbreviation List

Class: Front Matter

Abbreviations

AAP	American Academy of Pediatrics
ACC	American College of Cardiology
ACE	angiotensin-converting enzyme
ACLS	advanced cardiovascular life support
ACOG	American Congress of Obstetricians and Gynecologists
AHA	American Heart Association
ALT	alanine aminotransferase
ANC	absolute neutrophil count
aPTT	activated partial thromboplastin time
ARDS	acute respiratory distress syndrome
ASBMT	American Society of Bone Marrow Transplantation
ASCO	American Society of Clinical Oncology
AST	aspartate aminotransferase
ATS	American Thoracic Society
AUC	area under the serum concentration-time curve
AV	atrioventricular
BP	blood pressure
bpm	beats per minute
BUN	blood urea nitrogen
CABG	coronary artery bypass grafting
CAD	coronary artery disease
CAPD	continuous ambulatory peritoneal dialysis
CBC	complete blood count
CDC	US Centers for Disease Control and Prevention
CHD	coronary heart disease
CHF	congestive heart failure
CK	creatine kinase
Clcr	creatinine clearance
CNS	central nervous system
COX-1	cyclooxygenase-1
COPD	chronic obstructive pulmonary disease
CPK	creatine phosphokinase
CPR	cardiopulmonary resuscitation
CSF	cerebrospinal fluid
CYP	cytochrome P-450
DBP	diastolic blood pressure
DVT	deep-vein thrombosis
ECG	electrocardiogram
FDA	US Food and Drug Administration
FEV1	forced expiratory volume in 1 second
FSH	follicle-stimulating hormone
GABA	γ-amino butyric acid
GERD	gastroesophageal reflux disease
GFR	glomerular filtration rate
GI	gastrointestinal
GU	genitourinary
HBV	hepatitis B virus
HCTZ	hydrochlorothiazide
HCV	hepatitis C virus
HDL	high-density lipoprotein
HIV	human immunodeficiency virus
IDSA	Infectious Diseases Society of America
IgE	immune globulin E
IgG	immune globulin G
IgM	immune globulin M
IM	intramuscular
INR	international normalized rate
IOP	intraocular pressure
IV	intravenous
JNC 7	Joint National Committee on the Prevention, Detection, and Treatment of Hypertension
LDH	lactate dehydrogenase
LDL	low-density lipoprotein
LH	luteinizing hormone
MAO	monoamine oxidase
MI	myocardial infarction
MIC	minimum inhibitory concentration
NIH	National Institutes of Health
NSAIA	nonsteroidal anti-inflammatory agents
NYHA	New York Heart Association
OTC	over-the-counter or nonprescription
PCI	percutaneous coronary intervention
PE	pulmonary embolism
PSA	prostate-specific antigen
PT	prothrombin time
PTT	partial thromboplastin time
PVC	polyvinyl chloride
RBC	red blood cell
SA	sinoatrial
SBP	systolic blood pressure
Scr	serum creatinine concentration
SIADH	syndrome of inappropriate antidiuretic hormone secretion
SNRI	selective serotonin- and norepinephrine-reuptake inhibitor
SSRI	selective serotonin-reuptake inhibitor
Sub-Q	subcutaneous
TIA	transient ischemic attack
TSH	thyrotropin, thyroid-stimulating hormone
UGT	uridine diphosphate-glucuronosyltransferase
ULN	upper limit of normal
USPHS	US Public Health Service
VLDL	very low density lipoprotein
VF	ventricular fibrillation
VPCs	ventricular premature complexes
VT	ventricular tachycardia
WBC	white blood cell
WHO	World Health Organization

Disclaimer

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.

The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions September 01, 2011. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.

AK-Dilate Drops

Pronunciation: fen-il-EF-rin
Generic Name: Phenylephrine
Brand Name: Examples include AK-Dilate and Neofrin

AK-Dilate Drops are used for:

Constricting the blood vessels in the eye and dilating the pupil in certain eye surgeries, certain inflammatory conditions of the eye, or glaucoma. It may also be used for other conditions as determined by your doctor.

AK-Dilate Drops are a decongestant and mydriatic. It works by narrowing blood vessels in the eye and widening the pupil.

Do NOT use AK-Dilate Drops if:

• you are allergic to any ingredient in AK-Dilate Drops


• you have narrow-angle glaucoma or you are at risk for narrow-angle glaucoma


• you have severe narrowing of the blood vessels in the heart or brain


• the patient is a child

Contact your doctor or health care provider right away if any of these apply to you.

Before using AK-Dilate Drops:

Some medical conditions may interact with AK-Dilate Drops. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

• if you are pregnant, planning to become pregnant, or are breast-feeding


• if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement


• if you have allergies to medicines, foods, or other substances


• if you have heart disease, glaucoma, high blood pressure, or an overactive thyroid


• if you have had a recent eye injury or you have dry eyes


• if you are taking medicine for high blood pressure

Some MEDICINES MAY INTERACT with AK-Dilate Drops. Tell your health care provider if you are taking any other medicines, especially any of the following:

• Atropine, beta-blockers (eg, propranolol), droxidopa, furazolidone, guanethidine, methyldopa, monoamine oxidase (MAO) inhibitors (eg, phenelzine), reserpine, or tricyclic antidepressants (eg, amitriptyline) because the risk of serious side effects, such as high blood pressure and irregular heartbeat, may be increased

This may not be a complete list of all interactions that may occur. Ask your health care provider if AK-Dilate Drops may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use AK-Dilate Drops:

Use AK-Dilate Drops as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• AK-Dilate Drops are for use in the eye only. Avoid contact with your nose or mouth.


• To use AK-Dilate Drops, first, wash your hands. Tilt your head back. Using your index finger, pull the lower eyelid away from the eye to form a pouch. Drop the medicine into the pouch and gently close your eyes. Immediately use your finger to apply pressure to the inside corner of the eye for 1 to 2 minutes. Do not blink. Remove excess medicine around your eye with a clean tissue, being careful not to touch your eye. Wash your hands to remove any medicine that may be on them.


• To prevent germs from contaminating your medicine, do not touch the applicator tip to any surface, including your eye. Keep the container tightly closed.


• Do not wear contact lenses while you are using AK-Dilate Drops. Sterilize contact lenses according to the manufacturer's directions and check with your doctor before using them.


• Do not use AK-Dilate Drops if it is brown or contains particles.


• If you miss a dose of AK-Dilate Drops, use it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.

Ask your health care provider any questions you may have about how to use AK-Dilate Drops.

Important safety information:

• Before you have any medical or dental treatments, emergency care, or surgery, tell the doctor or dentist that you are using AK-Dilate Drops.


• Lab tests, including blood pressure, may be performed to monitor your progress or to check for side effects. Be sure to keep all doctor and lab appointments.


• Use AK-Dilate Drops with caution in the ELDERLY because they may be more sensitive to its effects, especially heart problems.


• AK-Dilate Drops are not recommended for use in CHILDREN. Safety and effectiveness have not been confirmed.


• PREGNANCY and BREAST-FEEDING: It is unknown if AK-Dilate Drops can cause harm to the fetus. If you become pregnant, discuss with your doctor the benefits and risks of using AK-Dilate Drops during pregnancy. It is unknown if AK-Dilate Drops are excreted in breast milk. If you are or will be breast-feeding while you are using AK-Dilate Drops, check with your doctor or pharmacist to discuss the risks to your baby.

Possible side effects of AK-Dilate Drops:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Burning or stinging of the eye; headache; seeing "floaters."

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); chest pain; confusion; constricted pupil; excitability; fainting; fast, slow, or irregular heartbeat; numbness of an arm or leg; one-sided weakness; severe or persistent headache; severe stomach pain; sudden severe dizziness, fainting, or vomiting; vision or speech changes.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: AK-Dilate side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.

Proper storage of AK-Dilate Drops:

Store AK-Dilate Drops at room temperature, between 68 and 77 degrees F (20 and 25 degrees C), in a tightly closed container. Store away from heat, moisture, and light. Do not store in the bathroom. Keep AK-Dilate Drops out of the reach of children and away from pets.

General information:

• If you have any questions about AK-Dilate Drops, please talk with your doctor, pharmacist, or other health care provider.


• AK-Dilate Drops are to be used only by the patient for whom it is prescribed. Do not share it with other people.


• If your symptoms do not improve or if they become worse, check with your doctor.


• Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about AK-Dilate Drops. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More AK-Dilate resources

• AK-Dilate Side Effects (in more detail)
• AK-Dilate Use in Pregnancy & Breastfeeding
• AK-Dilate Drug Interactions
• AK-Dilate Support Group
• 0 Reviews for AK-Dilate - Add your own review/rating

Compare AK-Dilate with other medications

• Eye Dryness/Redness
• Eye Redness/Itching
• Pupillary Dilation

Hybrisil

Dosage Form: gel

Hybrisil Description

DESCRIPTION: The topical corticosteroids constitute a class of primary synthetic steroids used as anti-inflammatory and anti-pruritic agents. Hybrisil™ Topical Silicone Gel contains methylpremethylprednisolone acetate, USP (CAS 53-36-1)

Chemical Name: Pregna-1,4-diene-3,20-dione, 21 - (acetyloxy) - 11,17 - dihydroxy - 6 - methyl - ,(6α,11ß) - ,11ß,17,21 - Trihydroxy - 6α - methylpregna - 1,4 - diene - 3,20 - dione 21-acetate.  It has a molecular formula of C24H32O6 and a molecular weight of 416.51.

Contains: Methylpremethylprednisolone acetate 1.0% in a base of: silicone cross-polymers, alcohol, cyclomethicones, propylene glycol, PEG-12 glyceryl dimyristate, and benzyl alcohol.

Hybrisil - Clinical Pharmacology

Topical corticosteroids share anti-inflammatory, anti-pruritic and vasoconstrictive actions.

The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear.  Various laboratory methods, including vasoconstriction assays are used to compare and predict potencies and or clinical efficacies of the topical corticosteroids.  There is some evidence to suggest that a recognizable correlation exists between vasoconstrictive potency and therapeutic efficacy in man.

Pharmacokinetics

The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier and the use of occlusive dressings.

Topical corticosteroids can be absorbed from normal intact skin.  Inflammation and /or other diseases processes in the skin increase percutaneous absorption.  Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids.  Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses.  (see DOSAGE AND ADMINISTRATION)

Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids.  Corticosteroids are bound to plasma proteins in varying degrees.  Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys.  Some of the topical corticosteroids and their metabolites are also excreted into the bile.

Indications and Usage for Hybrisil

Hybrisil™ topical gel is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses, including those associated with the formation of scar tissue.

Contraindications

Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. 

Precautions

General: Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing’s syndrome, hyperglycemia and glucosuria in some patients.

Conditions which augment systemic absorption include the application of more potent steroid use over large surface areas, prolonged use and addition of occlusive dressings.

Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests.  If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of applications, or to substitute a less potent steroid.

Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug.  Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids.

Children may absorb proportionately larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity.  (See PRECAUTIONS-Pediatric Use)

This medication contains alcohol.   It may produce irritation or burning sensations on open lesions.  If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.

As with any topical corticosteroid product, prolonged use may produce atrophy of the skin and subcutaneous tissues.  When used on intertriginous or flexor areas, or on the face, this may occur even with short-term use.

In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted.  If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled. 

Information for the Patient

Patients using topical corticosteroids should receive the following information and instructions:

1.    This medication is to be used as directed by the physician.  It is for external use only.  Avoid contact with the eyes. 

2.    Patients should be advised not to use this medication for any disorder other than for which it is prescribed.

3.    Treated skin areas should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician.

4.    Patients should report any signs of local adverse reactions, especially under occlusive dressing.

5.    Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area as these garments may constitute occlusive dressings.

Laboratory Tests

The urinary free cortisol test and the ACTH suppression test may be helpful in evaluating the HPA axis suppression.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term animal studies have not been performed to evaluate the carcinogenic potential of the effect of topical corticosteroids on fertility.

Studies to determine mutagenicity with prednisolone and hydrocortisone may have revealed negative results.

Pregnancy Category C

Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels.  The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals.  There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids.  Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.  Drugs of this class should not be used extensively on pregnant patients in large amounts or for prolonged periods of time. 

Nursing Mothers

It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk.  Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant.  Nevertheless, caution should be exercised when topical corticosteroids are administered to nursing women.

Pediatric Use

Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing’s syndrome than mature patients because of a larger skin surface area to body weight ratio.  Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing’s syndrome and intracranial hypertension have been reported in children receiving topical corticosteroids.  Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels and absence of response to ACTH stimulation.  Manifestation of intracranial hypertension include bulging fontanelles, headaches and bilateral papilledema.

Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen.  Chronic corticosteroid therapy may interfere with the growth and development of children.

Adverse Reactions

The following local adverse reactions are reported infrequently with topical corticosteroids but may occur more frequently with the use of occlusive dressings.  These reactions are listed in an approximate decreasing order of occurrence:

Burning, Itching, Irritation, Dryness, Folliculitis, Hypertrichosis, Acneiform eruptions, Hypopigmentation, Perioral dermatitis, Allergic contract dermatitis, Maceration of the skin, Secondary infection, Skin atrophy, Striae and Miliaria.

Overdosage

topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS)

Hybrisil Dosage and Administration

Hybrisil™ (methylpremethylprednisolone acetate 1%) silicone gel should be applied to the affected area as a thin film two or three times daily depending on the severity of the condition.

Occlusive dressings may be used for management of recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

CAUTION

If medication accidentally gets in the eyes, wash thoroughly with water and contact a physician immediately.  Keep out of the reach of children.

How is Hybrisil Supplied

in 30 gm bottle with pump.  Prescription only.

US Patents:    Pending.    

Revised April 2011

Image: Bottle Label

label_cd01.jpg

Image: Carton Label

uc_CD01.jpg

Hybrisil  methylpremethylprednisolone acetate  gel

Product Information Product Type HUMAN PRESCRIPTION DRUG NDC Product Code (Source) 55379-405 Route of Administration TOPICAL DEA Schedule

Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength Methylpremethylprednisolone acetate (Methylprednisolone) Methylpremethylprednisolone acetate 10 mg  in 1 g

Inactive Ingredients Ingredient Name Strength No Inactive Ingredients Found

Product Characteristics Color      Score      Shape Size Flavor Imprint Code Contains

Packaging # NDC Package Description Multilevel Packaging 1 55379-405-31 1 BOTTLE In 1 CARTON contains a BOTTLE, PUMP (55379-405-30) 1 55379-405-30 30 g In 1 BOTTLE, PUMP This package is contained within the CARTON (55379-405-31)

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
unapproved drug other		05/05/2010

Labeler - BioZone Laboratories, Inc. (555564293)

Revised: 04/2011BioZone Laboratories, Inc.

More Hybrisil resources

• Hybrisil Side Effects (in more detail)
• Hybrisil Drug Interactions
• Hybrisil Support Group
• 0 Reviews · Be the first to review/rate this drug

Lariam

Pronunciation: ME-floe-kwin
Generic Name: Mefloquine
Brand Name: Generic only. No brands available.

Lariam is used for:

Treating or preventing malaria.

Lariam is an antimalarial agent. Exactly how it works to kill sensitive malaria parasites is not known.

Do NOT use Lariam if:

• you are allergic to any ingredient in Lariam or to a similar medicine (eg, quinine, quinidine)


• you do not already have malaria and you currently have depression, a recent history of mental illness (eg, anxiety disorder, depression, psychosis, schizophrenia) or a history of seizures


• you are taking chloroquine, halofantrine, ketoconazole, quinidine, or quinine

Contact your doctor or health care provider right away if any of these apply to you.

Before using Lariam:

Some medical conditions may interact with Lariam. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

• if you are pregnant, planning to become pregnant, or are breast-feeding


• if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement


• if you have allergies to medicines, foods, or other substances


• if you have a history of seizures, heart problems (eg, irregular heartbeat), blood clotting problems, liver problems, diabetes, mental or mood problems (eg, depression), or suicidal thoughts or actions


• if you are taking medicine for diabetes (eg, glyburide) or an anticoagulant (eg, warfarin)


• if you are scheduled to receive a vaccine

Some MEDICINES MAY INTERACT with Lariam. Tell your health care provider if you are taking any other medicines, especially any of the following:

• Antiarrhythmics (eg, amiodarone, propafenone, quinidine), certain antihistamines (eg, astemizole, terfenadine), beta-blockers (eg, propranolol), calcium channel blockers (eg, amlodipine, verapamil), chloroquine, dofetilide, halofantrine, hydroxychloroquine, ketoconazole, paliperidone, phenothiazines (eg, thioridazine), quinine, tricyclic antidepressants (eg, amitriptyline), or ziprasidone because the risk of heart problems (eg, irregular heartbeat) or seizures may be increased


• Anticoagulants (eg, warfarin) because the risk of bleeding may be increased


• Rifampin because it may decrease Lariam's effectiveness


• Anticonvulsants (eg, valproic acid, carbamazepine, phenobarbital, phenytoin) because their effectiveness may be decreased by Lariam

This may not be a complete list of all interactions that may occur. Ask your health care provider if Lariam may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine

How to use Lariam:

Use Lariam as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Lariam comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Lariam refilled.


• Take Lariam by mouth with a full glass of water (8 oz/240 mL) right after you eat your main meal. Do not take it on an empty stomach.


• If the tablets cannot be swallowed whole, they may be crushed and mixed with a small amount of water, milk, or other beverage. Be sure to drink all the liquid so that you receive the entire dose.


• Lariam may cause vomiting, especially in children. Check with your doctor to see if you should take another dose if you vomit after taking Lariam.


• If you are taking Lariam to prevent malaria, begin taking it 1 week before traveling. Continue to take it for 4 weeks after leaving the malaria area. If you cannot complete the treatment, contact your doctor.


• If you are taking other medicines, ask your doctor if you should start taking Lariam 2 to 3 weeks before traveling in order to make sure that the combination of medicines is well tolerated.


• Weekly doses of Lariam should be taken regularly, on the same day of each week, preferably after the main meal of the day.


• Continue to use Lariam for the full course of treatment. Do not miss any doses. Malaria can be life-threatening.


• If you miss a dose of Lariam and you are taking it to prevent infection, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Lariam.

Important safety information:

• Lariam may cause drowsiness, dizziness, lightheadedness, or a loss of balance. These effects may be worse if you take it with alcohol or certain medicines. Effects of Lariam may continue for a period of time (eg, several weeks), even after you stop taking it. Use Lariam with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.


• Carry an ID card at all times that says you take Lariam.


• Tell your doctor or dentist that you take Lariam before you receive any medical or dental care, emergency care, or surgery.


• Lariam may decrease the effectiveness of live vaccines. Check with your doctor before you receive any vaccines while you are using Lariam.


• Women who may become pregnant should use effective birth control while taking Lariam and for up to 3 months after stopping treatment. Check with your doctor if you have questions about using birth control.


• Contact your doctor right away if you experience mental or mood changes (eg, anxiety, depression, restlessness, confusion, hallucinations, paranoia). You may need to stop taking Lariam and start a different malaria medicine.


• If you have to stop taking Lariam for any reason and you do not have access to a doctor or to another malaria medicine, leave the malaria area and contact a doctor as soon as possible. Leaving the area may not protect you from contracting malaria. You may still need to take another medicine to prevent the disease.


• No medicine is completely effective against malaria. While you are in an area where malaria exists, use bed nets and insect repellents and wear protective clothing (long sleeves and long pants) to decrease your risk. In some situations, you may want to pre-wash your clothes with permethrin, a mosquito repellent that may be effective for weeks after use. Ask your doctor for other ways to protect yourself.


• Contact your health care provider at once if you develop a fever or flu-like symptoms (eg, chills, headache, muscle pains) after returning from an area where malaria exists.


• If you are using Lariam to treat malaria and your symptoms do not improve within 48 to 72 hours, contact your doctor right away.


• If your doctor tells you to stop taking Lariam, you will need to wait for at least 15 weeks before you start to take certain other medicines (eg, halofantrine, ketoconazole). Ask your doctor when you should start to take any new medicines after you stop Lariam.


• Lab tests, including liver function, complete blood cell count, and eye exams, may be performed while you use Lariam. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.


• Use Lariam with caution in the ELDERLY; they may be more sensitive to its effects, especially heart problems.


• Lariam should not be used in CHILDREN who are younger than 6 months old or who weigh less than 44 lbs (20 kg); safety and effectiveness in these children have not been confirmed.


• PREGNANCY and BREAST-FEEDING: Do not become pregnant while you are taking Lariam. If you think you may be pregnant, contact your doctor. You will need to discuss the benefits and risks of using Lariam while you are pregnant. Lariam is found in breast milk. Do not breast-feed while taking Lariam.

Possible side effects of Lariam:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Diarrhea; dizziness; drowsiness; headache; lightheadedness; loss of appetite; muscle aches; nausea; stomach pain or upset; strange dreams; tiredness; trouble sleeping; vomiting.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); bizarre behavior; chest pain; fainting; fast, slow, or irregular heartbeat; flu-like symptoms (eg, chills, fever, headache, muscle pain); loss of balance or coordination; memory problems; mental or mood changes (eg, anxiety, confusion, depression, hallucinations, mood changes, paranoia, restlessness); numbness or tingling of the hands or feet; red, swollen or blistered skin; ringing in the ears; seizures; severe or persistent cough; shortness of breath; suicidal thoughts or attempts; symptoms of liver problems (eg, dark urine, pale stools, persistent stomach pain or loss of appetite, persistent tiredness, yellowing of the skin or eyes); tremor; vision changes.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: Lariam side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include diarrhea; fast, slow, or irregular heartbeat; mental or mood changes; vomiting.

Proper storage of Lariam:

Store Lariam at 77 degrees F (25 degrees C). Brief storage at temperatures between 59 and 86 degrees F (15 and 30 degrees C) is permitted. Store away from heat, moisture, and light. Do not store in the bathroom. Keep out of the reach of children and away from pets.

General information:

• If you have any questions about Lariam, please talk with your doctor, pharmacist, or other health care provider.


• Lariam is to be used only by the patient for whom it is prescribed. Do not share it with other people.


• If your symptoms do not improve or if they become worse, check with your doctor.


• Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Lariam. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Lariam resources

• Lariam Side Effects (in more detail)
• Lariam Use in Pregnancy & Breastfeeding
• Drug Images
• Lariam Drug Interactions
• Lariam Support Group
• 0 Reviews for Lariam - Add your own review/rating

• Lariam Prescribing Information (FDA)


• Lariam Advanced Consumer (Micromedex) - Includes Dosage Information


• Lariam Concise Consumer Information (Cerner Multum)


• Lariam Monograph (AHFS DI)


• Mefloquine Prescribing Information (FDA)

Compare Lariam with other medications

• Malaria
• Malaria Prevention

Tresaderm

Dosage Form: FOR ANIMAL USE ONLY
Tresaderm®

(thiabendazole, dexamethasone, neomycin sulfate solution)

NADA 042-633, Approved by the FDA.

Dermatologic Solution

CAUTION

Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.

Tresaderm Description

Dermatologic Solution Tresaderm® (thiabendazole, dexamethasone, neomycin sulfate solution) contains the following active ingredients per mL: 40 mg thiabendazole, 1 mg dexamethasone, 3.2 mg neomycin (from neomycin sulfate). Inactive ingredients: glycerin, propylene glycol, purified water, hypophosphorous acid, calcium hypophosphite; about 8.5% ethyl alcohol and about 0.5% benzyl alcohol.

INDICATIONS

Dermatologic Solution Tresaderm is indicated as an aid in the treatment of certain bacterial, mycotic, and inflammatory dermatoses and otitis externa in dogs and cats. Both acute and chronic forms of these skin disorders respond to treatment with Tresaderm. Many forms of dermatosis are caused by bacteria (chiefly Staphylococcus aureus, Proteus vulgaris and Pseudomonas aeruginosa). Moreover, these organisms often act as opportunistic or concurrent pathogens that may complicate already established mycotic skin disorders, or otoacariasis caused by Otodectes cynotis. The principal etiologic agents of dermatomycoses in dogs and cats are species of the genera Microsporum and Trichophyton. The efficacy of neomycin as an antibacterial agent, with activity against both gram-negative and gram-positive pathogens, is well documented. Detailed studies in various laboratories have verified the significant activity thiabendazole displays against the important dermatophytes. Dexamethasone, a synthetic adrenocorticoid steroid, inhibits the reaction of connective tissue to injury and suppresses the classic inflammatory manifestations of skin disease. The formulation for Tresaderm combines these several activities in a complementary form for control of the discomfort and direct treatment of dermatitis and otitis externa produced by the above-mentioned infectious agents.

Tresaderm Dosage and Administration

Prior to the administration of Dermatologic Solution Tresaderm, remove the ceruminous, purulent or foreign materials from the ear canal, as well as the crust which may be associated with dermatoses affecting other parts of the body. The design of the container nozzle safely allows partial insertion into the ear canal for ease of administration. The amount to apply and the frequency of treatment are dependent upon the severity and extent of the lesions. Five to 15 drops should be instilled in the ear twice daily. In treating dermatoses affecting other than the ear the surface of the lesions should be well moistened (2 to 4 drops per square inch) with Dermatologic Solution Tresaderm twice daily. The volume required will be dependent upon the size of the lesion.

Application of Tresaderm should be limited to a period of not longer than one week.

Precautions

On rare occasions dogs may be sensitive to neomycin. In these animals, application of the drug will result in erythema of the treated area, which may last 24 to 48 hours. Also, evidence of transient discomfort has been noted in some dogs when the drug was applied to fissured or denuded areas. The expression of pain may last 2 to 5 minutes. Application of Dermatologic Solution Tresaderm should be limited to periods not longer than one week.

While systemic side effects are not likely with topically applied corticosteroids, such a possibility should be considered if use of the solution is extensive and prolonged. If signs of salt and water retention or potassium excretion are noticed (increased thirst, weakness, lethargy, oliguria, gastrointestinal disturbances or tachycardia), treatment should be discontinued and appropriate measures taken to correct the electrolyte and fluid imbalance.

Store in a refrigerator 36 - 46°F (2 - 8°C).

Warning

For topical use in dogs and cats.

Avoid contact with eyes.

Keep this and all drugs out of the reach of children.

The Material Safety Data Sheet (MSDS) contains more detailed occupational safety information. To report adverse effects in users, to obtain an MSDS, or for assistance call 1-888-637-4251.

How is Tresaderm Supplied

Product 55871 - Dermatologic Solution Tresaderm Veterinary is supplied in 7.5 mL and 15 mL dropper bottles, each in 12 bottle boxes.

Marketed by

Merial Limited

Duluth, Georgia 30096-4640

(Merial Limited: Registered in England and Wales [Reg. No. 3332751] with registered offices at 27 Knightsbridge, London, SW1X 7QT, England and domesticated in Delaware, USA as Merial LLC).

© 2000 Merial. All rights reserved.

January 2002

Tresaderm is a registered trademark of Merial.

PRINCIPAL DISPLAY PANEL - 15 mL Bottle Carton

15 mL

Tresaderm ®

(thiabendazole, dexamethasone,

neomycin sulfate solution)

Dermatologic Solution

CAUTION: Federal (U.S.A.) law

restricts this drug to use by or on

the order of a licensed veterinarian.

Marketed by: Merial LLC,

Duluth, GA 30096-4640, U.S.A.

12 x 15 mL Bottles*

MERIAL

Tresaderm  dexamethasone, neomycin sulfate, and thiabendazole  solution

Product Information Product Type PRESCRIPTION ANIMAL DRUG NDC Product Code (Source) 50604-5587 Route of Administration TOPICAL DEA Schedule

Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength dexamethasone (dexamethasone) dexamethasone 1 mg  in 1 mL neomycin sulfate (neomycin) neomycin 3.2 mg  in 1 mL thiabendazole (thiabendazole) thiabendazole 40 mg  in 1 mL

Inactive Ingredients Ingredient Name Strength glycerin   propylene glycol   water   calcium hypophosphite   alcohol   benzyl alcohol

Product Characteristics Color      Score      Shape Size Flavor Imprint Code Contains

Packaging # NDC Package Description Multilevel Packaging 1 50604-5587-3 12 BOTTLE In 1 CARTON contains a BOTTLE, PLASTIC (50604-5587-1) 1 50604-5587-1 7.5 mL In 1 BOTTLE, PLASTIC This package is contained within the CARTON (50604-5587-3) 2 50604-5587-4 12 BOTTLE In 1 CARTON contains a BOTTLE, PLASTIC (50604-5587-2) 2 50604-5587-2 15 mL In 1 BOTTLE, PLASTIC This package is contained within the CARTON (50604-5587-4)

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NADA	NADA042633	11/09/1971

Labeler - Merial Limited (034393582)

Revised: 08/2010Merial Limited